ArticleBMC cancer2014

Novel treatment option for MUC16-positive malignancies with the targeted TRAIL-based fusion protein Meso-TR3.

Gunjal Garg et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.